Innoviva Q1 revenue $98M (+11% YoY); IST sales surge 37%; net income $186.6M

Innoviva, Inc.

2026-Q1 EPS reported $2.22 revenue$97,994,000

Total revenue $98.0M, up 11% YoY; GSK royalty revenue $58.6M (down from $61.3M).
Net product sales $41.4M (+37% YoY); US sales $34.2M led by GIAPREZA $19.7M, XACDURO $11.6M.
Net income $186.6M ($2.52 EPS) driven by $191.2M favorable fair value change in equity investments, primarily Armata Pharmaceuticals.
Repurchased 971,066 shares for $20.4M in Q1 under $125M share repurchase program.
NUZOLVENCE (zoliflodacin) FDA-approved Dec 2025; availability expected H2 2026.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 1.0

Innoviva, Inc. reported first quarter ended March 31, 2026 results: revenue $98.0 million, net income $186.6 million, EPS $2.52 basic earnings per share.

Period: first quarter ended March 31, 2026
Revenue: $98.0 million
Net income: $186.6 million
EPS: $2.52 basic earnings per share
Result: reported results

Exact text from the filing

and long-term shareholder value creation throughout variable market environments,” concluded Mr. Raifeld. Financial Highlights for the First Quarter of 2026 • Total revenue: $98.0 million, yielding 11% growth compared to $88.6 million for the first quarter 2025. • Royalty revenue: gross royalty revenue from Glaxo Group Limited (“GSK”) was $58.6 million, compared

View on SEC.gov

51 earnings releases filed in the last 30 days. Browse all earnings releases →

Innoviva, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-26-209044

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.